Loading
companiesCompany
Syndax Pharmaceuticals
Syndax Pharmaceuticals, of Waltham, Massachusetts, developed revumenib (Revuforj), the first menin inhibitor approved for leukaemia, proved in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation. It also makes axatilimab for chronic graft-versus-host disease, and resistance mutations in menin itself are the class's unsolved problem.
Overview
Syndax Pharmaceuticals, based in Waltham, Massachusetts, and listed as SNDX, developed revumenib, the first menin inhibitor approved for leukaemia. Revumenib, sold as Revuforj, was proved in the AUGMENT-101 trial in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, and the company also makes axatilimab, a CSF-1R antibody for chronic graft-versus-host disease. OnCo links it to acute myeloid leukaemia, to the revumenib drug record and to the AUGMENT-101 paper. Whether menin inhibitors move from relapsed disease into first-line combinations, and how the class handles resistance mutations in menin itself, are the open questions. Revumenib has its own page.
Headquarters
Waltham, MA, US
Scorecard
All companies#233of 1244 companies, score 22
- approved products +6
- targets +2
- modalities +2
- regions +1
- 24-month regulatory events +4
- registry trials +7
1 approved, 0 in phase 3, 0 earlier, 1 targets, 14 registry studies. Formula on the scorecards page.
Type
Biotech · SNDX
Stage
Public
Website
ApprovedSmall-molecule menin inhibitor
Revumenib · Revuforj
Revumenib (Revuforj) is the first menin inhibitor (2024), for acute leukaemias with KMT2A rearrangements or NPM1 mutations.
Similar pages
- PersonGhayas C. Issa
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Acute myeloid leukaemia.
- PersonEytan M. Stein
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Acute myeloid leukaemia.
- PairingMenin inhibitor + venetoclax + azacitidine
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Acute myeloid leukaemia.
- CompanyKura Oncology
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Acute myeloid leukaemia.
- TargetNPM1 mutation
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Acute myeloid leukaemia.
- TargetKMT2A (MLL) rearrangement
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Acute myeloid leukaemia.
- PersonEunice S. Wang
Shares Revumenib, Acute myeloid leukaemia.
- TermDifferentiation syndrome
Shares AUGMENT-101, Revumenib, Acute myeloid leukaemia.